EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns

D Quatannens, Y Verhoeven, S van der Heijden, D Peeters, J Claes, C Hermans, H Lambrechts, K Zwaenepoel, P van Dam, M Peeters, H Prenen, S Koljenovic und 6 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04343-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von D Quatannens und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Receptors, Immunologic, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In pancreatic ductal adenocarcinoma (PDAC), immune checkpoint inhibitors have shown limited efficacy, and the role of the TIGIT axis remains underexplored. This study aimed to characterize TIGIT axis components on protein level and their relationship to PD-1/PD-L1 expression in matched blood and tumor samples from PDAC patients to identify immunosuppressive mechanisms and fuel future strategies for immune checkpoint co-targeting in PDAC patients. EXPERIMENTAL DESIGN: Fresh tumor and peripheral blood samples were collected from PDAC patients undergoing surgical resection. Flow cytometry was performed on tumor-infiltrating lymphocytes and PBMCs to assess expression of TIGIT, DNAM-1, TACTILE, and PD-1. Ligands CD111, CD112, CD113, and CD155 were analyzed using immunohistochemistry. Additional RNA expression analysis (TCGA/GTEx) was used to evaluate ligand distribution and gene expression profiles. RESULTS: TIGIT was highly upregulated on intratumoral CD8⁺ T cells and regulatory T cells, frequently co-expressed with PD-1. DNAM-1 expression was significantly reduced in tumors. However, contrasting pattern emerges with Tregs, which uniquely upregulate DNAM-1 in the PDAC TME. In addition, CD112 and CD155 were broadly expressed, including novel stromal CD112 localization. NK cells were nearly absent intratumorally, correlating with DNAM-1 downregulation. CONCLUSIONS: Our findings identify TIGIT as a promising immunotherapeutic target in PDAC and suggest that dual checkpoint blockade (TIGIT/PD-1), alongside restoration of DNAM-1 signaling, may overcome immune suppression. These results provide mechanistic rationale to inform future clinical trials in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansLymphocytes, Tumor-InfiltratingT Lineage-Specific Activation Antigen 1FemaleMaleAntigens, Differentiation, T-LymphocyteT-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticProgrammed Cell Death 1 ReceptorTumor MicroenvironmentBiomarkers, TumorMiddle AgedB7-H1 AntigenReceptors, Virus

Stichwörter der Autor:innen

Immune checkpointsPancreatic cancerTIGIT axisTumor immune microenvironment

Substanzen

Receptors, ImmunologicTIGIT protein, humanT Lineage-Specific Activation Antigen 1poliovirus receptorAntigens, Differentiation, T-LymphocyteProgrammed Cell Death 1 ReceptorBiomarkers, TumorPDCD1 protein, humanB7-H1 AntigenReceptors, Virus

Autor:innen und Institutionen

  • Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
  • Department of Pathology, Antwerp University Hospital (UZA), Antwerp, Belgium.
  • Data Science Institute, I-Biostat, Hasselt University, Hasselt, Belgium.
  • Department of Oncology, Antwerp University Hospital (UZA), Antwerp, Belgium.
  • Department of Hepatobiliary Transplantation and Endocrine Surgery, Antwerp University Hospital (UZA), Antwerp, Belgium.
  • Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium. jonas.vanaudenaerde@uantwerpen.be.

Förderung

  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Quatannens, D., Verhoeven, Y., van der Heijden, S., Peeters, D., Claes, J., Hermans, C., Lambrechts, H., Zwaenepoel, K., van Dam, P., Peeters, M., Prenen, H., Koljenovic, S., De Waele, J., Faes, C., Lardon, F., Roeyen, G., Smits, E., & Van Audenaerde, J. (2026). Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04343-w

Vancouver

Quatannens D, Verhoeven Y, van der Heijden S, Peeters D, Claes J, Hermans C, et al. Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04343-w

BibTeX
@article{Quatannens2026,
  author = {Quatannens, D and Verhoeven, Y and van der Heijden, S and Peeters, D and Claes, J and Hermans, C and Lambrechts, H and Zwaenepoel, K and van Dam, P and Peeters, M and Prenen, H and Koljenovic, S and De Waele, J and Faes, C and Lardon, F and Roeyen, G and Smits, E and Van Audenaerde, J},
  title = {Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04343-w}
}
Kostenlos starten →